Kato T, Nemoto R, Mori H, Kumagai I
Cancer. 1980 Jul 1;46(1):14-21. doi: 10.1002/1097-0142(19800701)46:1<14::aid-cncr2820460103>3.0.co;2-n.
Mitomycin C (MMC) was microencapsulated with ethylcellulose. The microcapsules contained, on average, 80% of biologically active MMC and had a sustained-release property. The mean particle size was 224 micrometers so that the microcapsules were readily infused into a canine kidney through arterial catheterization. Ex vivo infusion demonstrated that the microcapsules lodged in the small arteries, mainly at the cortico-medullary junction, and released concentrated MMC into the surrounding tissue. In vivo experiments revealed that the canine kidneys infused with the microcapsules retained active MMC for more than 6 hours and showed extensive necrosis five days after the infusion. The kidneyks infused with nonencapsulated MMC rapidly excreted MMC and showed mild histologic changes. The blood level of MMC released from the intrarenal microcapsules was markedly reduced as compared with control levels. The results suggest that the potential therapeutic effect of intraarterial infusion of MMC microcapsules is a function of embolization and prolonged drug action, and that selective infusion of MMC microcapsules into tumor-supplying arteries could facilitate intensive topical chemotherapy with minimum systemic side-effects.
丝裂霉素C(MMC)用乙基纤维素进行微囊化。这些微囊平均含有80%的生物活性MMC,并具有缓释特性。平均粒径为224微米,因此这些微囊可通过动脉插管轻松注入犬肾。体外灌注表明,微囊滞留在小动脉中,主要位于皮质-髓质交界处,并将浓缩的MMC释放到周围组织中。体内实验显示,注入微囊的犬肾在灌注后6小时以上仍保留活性MMC,并在五天后出现广泛坏死。注入未微囊化MMC的肾脏迅速排泄MMC,并显示出轻微的组织学变化。与对照水平相比,肾内微囊释放的MMC血药浓度明显降低。结果表明,动脉内灌注MMC微囊的潜在治疗效果是栓塞和延长药物作用的结果,并且将MMC微囊选择性注入肿瘤供血动脉可促进强化局部化疗,同时使全身副作用最小化。